Xencor (NASDAQ:XNCR) Trading Down 3.9% - Should You Sell?

Xencor, Inc. (NASDAQ:XNCR - Get Free Report)'s share price traded down 3.9% on Friday . The company traded as low as $19.70 and last traded at $19.66. 67,569 shares were traded during trading, a decline of 87% from the average session volume of 537,709 shares. The stock had previously closed at $20.46.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. BMO Capital Markets reiterated an "outperform" rating and issued a $34.00 price target (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Piper Sandler upgraded shares of Xencor from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $20.00 to $30.00 in a report on Monday, December 2nd. Wedbush restated an "outperform" rating and issued a $38.00 price target on shares of Xencor in a report on Thursday, November 7th. Wells Fargo & Company initiated coverage on shares of Xencor in a research note on Thursday, December 12th. They set an "overweight" rating and a $37.00 price objective for the company. Finally, JPMorgan Chase & Co. raised their target price on shares of Xencor from $27.00 to $28.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $34.88.

Xencor Price Performance

The stock's 50 day simple moving average is $23.56 and its 200-day simple moving average is $21.08. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of -6.14 and a beta of 0.72. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23.

Xencor (NASDAQ:XNCR - Get Free Report) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm had revenue of $10.70 million for the quarter, compared to the consensus estimate of $14.59 million. During the same period in the prior year, the firm earned ($0.40) EPS. The firm's revenue was down 81.9% on a year-over-year basis. Equities research analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Insider Transactions at Xencor

In related news, CEO Bassil I. Dahiyat sold 3,366 shares of the firm's stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $24.02, for a total transaction of $80,851.32. Following the completion of the transaction, the chief executive officer now owns 352,615 shares of the company's stock, valued at $8,469,812.30. This trade represents a 0.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Alan Bruce Montgomery sold 13,301 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $27.03, for a total transaction of $359,526.03. Following the transaction, the director now owns 9,140 shares of the company's stock, valued at $247,054.20. This represents a 59.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 136,050 shares of company stock worth $3,277,609 over the last three months. 5.23% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Quarry LP acquired a new stake in shares of Xencor during the 2nd quarter worth approximately $36,000. GAMMA Investing LLC increased its holdings in Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 508 shares in the last quarter. KBC Group NV raised its position in shares of Xencor by 63.5% in the third quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company's stock worth $63,000 after acquiring an additional 1,213 shares during the period. Rockefeller Capital Management L.P. purchased a new stake in shares of Xencor during the 3rd quarter worth about $205,000. Finally, XTX Topco Ltd acquired a new stake in shares of Xencor during the 2nd quarter valued at about $196,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.